{"id":17058,"date":"2023-08-24T09:00:25","date_gmt":"2023-08-24T16:00:25","guid":{"rendered":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/?p=17058"},"modified":"2023-08-24T09:24:11","modified_gmt":"2023-08-24T16:24:11","slug":"how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported","status":"publish","type":"post","link":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/","title":{"rendered":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported"},"content":{"rendered":"

Content not available in all countries.<\/em><\/p>\n

Recent changes in health policies regarding molecular diagnostics, especially those involving infectious disease<\/a> syndromic panels and PCR testing for infectious agents, have increased the challenges labs face when designing infectious disease molecular panels that are both clinically relevant and<\/em> payor-supported.<\/p>\n

As Marcus Cognetti, Co-Founder of national lab network P4 Diagnostix, explains in this webinar<\/a>, reference labs and other testing facilities are now at an \u201cinflection point\u201d created by evolving guidelines, the end of the SARS-CoV-2 public health emergency, and diminished COVID-19 testing volumes. \u201cThere are labs like P4 that were in infectious disease and molecular testing beforehand, but there are many others afterwards that had spun up testing for COVID and are now looking or have been looking for new ways to utilize those testing platforms,\u201d he said.<\/p>\n

Watch the webinar<\/a><\/p>\n

\"\"<\/p>\n

 <\/p>\n

In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.<\/p>\n

Designing molecular panels to meet customer needs<\/h2>\n

When it comes to content selection, Cognetti recommends that labs begin by identifying their customer base. Then, they should pick markers and panels that are tailored to address the specific needs of these clients and the patient populations they serve.<\/p>\n

\u201cYou can look at existing tests for guidance on where to start,\u201d he explained. \u201cBut you need to design the test off of medical efficacy and understanding what the reimbursement landscape is going to be with your providers. Design it for the best outcome in terms of what that test result will look like.\u201d<\/p>\n

Building molecular panels is typically a complex process since content selection not only differs between diseases, but also depends on each lab\u2019s capabilities and business goals. Cognetti says Diagnostix takes a multi-dynamic approach and is constantly adapting panels based on current markers, new and existing literature, and ongoing analysis of different modalities.<\/p>\n

Growing importance of antimicrobial stewardship when selecting gene targets<\/h2>\n

The webinar also covered emerging concerns about antimicrobial resistance (AMR<\/a>). As Dr. Frenkel points out, researchers estimate that in 2019 there were 4.95 million deaths associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR\u2014and that is more than the number of people who died from HIV\/AIDS<\/a> and malaria that year combined [1]. \u201cAntimicrobial resistance is becoming a more central conversation,\u201d Dr. Frenkel said. \u201cIt\u2019s the silent pandemic.\u201d<\/p>\n

\u201cAntimicrobial resistance is critical in healthcare. It\u2019s going to affect our rates of hospital-acquired infections and admissions, and whether or not these infections are even treatable,\u201d continued Dr. Frenkel. \u201cWe fear in the future that even the simplest infection could be impossible to treat due to antimicrobial resistance.” With increased awareness of the dangers of AMR, guidelines are beginning to change.<\/p>\n

To help ensure antibiotics are tailored appropriately, \u201cyou almost want to design the panel backwards,\u201d Dr. Frenkel explained. He suggests answering questions such as: What are we trying to diagnose? What are the most common microbes causing this? What are the most common associated resistances to those microbes?<\/em> \u201cWorking from that side of the equation we often find is best to determine what to put on these panels,\u201d he added.<\/p>\n

To learn more about selecting relevant organisms and antimicrobial resistance gene targets for diagnostic testing, watch How to choose clinically relevant targets for your infectious disease panels<\/em><\/a> on demand. The 60-minute webinar is full of practical advice to help labs navigate today\u2019s clinical evidence requirements, assess emerging AMR concerns, and develop successful reimbursement strategies.<\/p>\n

To learn more about Thermo Fisher Scientific\u2019s infectious disease testing solutions, please visit here<\/a>.<\/p>\n

    \n
  1. \n
      \n
    1. The Lancet | Global burden of bacterial antimicrobial resistance in 2019: a systemic analysis<\/a><\/li>\n<\/ol>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Content not available in all countries. Recent changes in health policies regarding molecular diagnostics, especially those involving infectious disease syndromic panels and PCR testing for infectious agents, have increased the challenges labs face when designing infectious disease molecular panels that are both clinically relevant and payor-supported. As Marcus Cognetti, Co-Founder of national lab network P4<\/p>\n","protected":false},"author":1556,"featured_media":17059,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_monsterinsights_skip_tracking":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[10],"tags":[121,236,41,171],"division":[],"class_list":{"0":"post-17058","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-science-and-education","8":"tag-content-article","9":"tag-molecular-testing","10":"tag-pcr","11":"tag-uti","12":"entry"},"_selected_authors":"","_selected_reviewers":"","acf":[],"yoast_head":"\nHow to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported - Clinical Conversations<\/title>\n<meta name=\"description\" content=\"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported\" \/>\n<meta property=\"og:description\" content=\"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Conversations\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thermofisher\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-24T16:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T16:24:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"onbeat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@thermofisher\" \/>\n<meta name=\"twitter:site\" content=\"@thermofisher\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"onbeat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/\"},\"author\":{\"name\":\"onbeat\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/#\\\/schema\\\/person\\\/1b2dd2b0198769d0c9e623039257ceb8\"},\"headline\":\"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported\",\"datePublished\":\"2023-08-24T16:00:25+00:00\",\"dateModified\":\"2023-08-24T16:24:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/\"},\"wordCount\":657,\"image\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/wp-content\\\/uploads\\\/sites\\\/18\\\/2023\\\/07\\\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg\",\"keywords\":[\"content-Article\",\"Molecular Testing\",\"PCR\",\"UTI\"],\"articleSection\":[\"Science and education\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/\",\"url\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/\",\"name\":\"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported - Clinical Conversations\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/wp-content\\\/uploads\\\/sites\\\/18\\\/2023\\\/07\\\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg\",\"datePublished\":\"2023-08-24T16:00:25+00:00\",\"dateModified\":\"2023-08-24T16:24:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/#\\\/schema\\\/person\\\/1b2dd2b0198769d0c9e623039257ceb8\"},\"description\":\"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/wp-content\\\/uploads\\\/sites\\\/18\\\/2023\\\/07\\\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg\",\"contentUrl\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/wp-content\\\/uploads\\\/sites\\\/18\\\/2023\\\/07\\\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.thermofisher.com\\\/blog\\\/clinical-conversations\\\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/#website\",\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/\",\"name\":\"Clinical Conversations\",\"description\":\"Molecular and antibody testing content for clinical lab professionals and clinicians\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/clinical-conversations\\\/#\\\/schema\\\/person\\\/1b2dd2b0198769d0c9e623039257ceb8\",\"name\":\"onbeat\",\"url\":\"https:\\\/\\\/admin.acceleratingscience.com\\\/author\\\/onbeat\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported - Clinical Conversations","description":"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/","og_locale":"en_US","og_type":"article","og_title":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported","og_description":"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.","og_url":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/","og_site_name":"Clinical Conversations","article_publisher":"https:\/\/www.facebook.com\/thermofisher","article_published_time":"2023-08-24T16:00:25+00:00","article_modified_time":"2023-08-24T16:24:11+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg","type":"image\/jpeg"}],"author":"onbeat","twitter_card":"summary_large_image","twitter_creator":"@thermofisher","twitter_site":"@thermofisher","twitter_misc":{"Written by":"onbeat","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#article","isPartOf":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/"},"author":{"name":"onbeat","@id":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/#\/schema\/person\/1b2dd2b0198769d0c9e623039257ceb8"},"headline":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported","datePublished":"2023-08-24T16:00:25+00:00","dateModified":"2023-08-24T16:24:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/"},"wordCount":657,"image":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#primaryimage"},"thumbnailUrl":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg","keywords":["content-Article","Molecular Testing","PCR","UTI"],"articleSection":["Science and education"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/","url":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/","name":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported - Clinical Conversations","isPartOf":{"@id":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#primaryimage"},"image":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#primaryimage"},"thumbnailUrl":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg","datePublished":"2023-08-24T16:00:25+00:00","dateModified":"2023-08-24T16:24:11+00:00","author":{"@id":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/#\/schema\/person\/1b2dd2b0198769d0c9e623039257ceb8"},"description":"In the webinar, Cognetti is joined by Ari Frenkel, MD, Co-Founder and Chief Science Officer at Arkstone Medical Solutions, for an informative and topical discussion exploring how labs can best chart a path forward in this evolving regulatory landscape. The conversation covered how to review the existing clinical literature and guidelines, and gaps in clinical utility that will impact reimbursement.","breadcrumb":{"@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#primaryimage","url":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg","contentUrl":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1.jpg","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/how-to-build-infectious-disease-molecular-panels-that-are-clinically-relevant-and-payor-supported\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/"},{"@type":"ListItem","position":2,"name":"How to Build Infectious Disease Molecular Panels That Are Clinically Relevant and Payor-Supported"}]},{"@type":"WebSite","@id":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/#website","url":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/","name":"Clinical Conversations","description":"Molecular and antibody testing content for clinical lab professionals and clinicians","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/admin.acceleratingscience.com\/clinical-conversations\/#\/schema\/person\/1b2dd2b0198769d0c9e623039257ceb8","name":"onbeat","url":"https:\/\/admin.acceleratingscience.com\/author\/onbeat\/"}]}},"taxonomy_info":{"category":[{"value":10,"label":"Science and education"}],"post_tag":[{"value":121,"label":"content-Article"},{"value":236,"label":"Molecular Testing"},{"value":41,"label":"PCR"},{"value":171,"label":"UTI"}]},"featured_image_src_large":["https:\/\/admin.acceleratingscience.com\/clinical-conversations\/wp-content\/uploads\/sites\/18\/2023\/07\/PG2816-PJT10511-COL025349-GTS-Custom-Shutterstock-image-search-and-purchase-F-1200x628-1-1024x536.jpg",760,398,true],"author_info":{"display_name":"onbeat","author_link":"https:\/\/admin.acceleratingscience.com\/author\/onbeat\/"},"comment_info":0,"category_info":[{"term_id":10,"name":"Science and education","slug":"science-and-education","term_group":0,"term_taxonomy_id":10,"taxonomy":"category","description":"","parent":0,"count":117,"filter":"raw","meta":[],"cat_ID":10,"category_count":117,"category_description":"","cat_name":"Science and education","category_nicename":"science-and-education","category_parent":0}],"tag_info":[{"term_id":121,"name":"content-Article","slug":"content-article","term_group":0,"term_taxonomy_id":121,"taxonomy":"post_tag","description":"","parent":0,"count":93,"filter":"raw","meta":[]},{"term_id":236,"name":"Molecular Testing","slug":"molecular-testing","term_group":0,"term_taxonomy_id":236,"taxonomy":"post_tag","description":"","parent":0,"count":20,"filter":"raw","meta":[]},{"term_id":41,"name":"PCR","slug":"pcr","term_group":0,"term_taxonomy_id":41,"taxonomy":"post_tag","description":"","parent":0,"count":35,"filter":"raw","meta":[]},{"term_id":171,"name":"UTI","slug":"uti","term_group":0,"term_taxonomy_id":171,"taxonomy":"post_tag","description":"","parent":0,"count":13,"filter":"raw","meta":[]}],"_links":{"self":[{"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/posts\/17058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/users\/1556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/comments?post=17058"}],"version-history":[{"count":0,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/posts\/17058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/media\/17059"}],"wp:attachment":[{"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/media?parent=17058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/categories?post=17058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/tags?post=17058"},{"taxonomy":"division","embeddable":true,"href":"https:\/\/www.thermofisher.com\/blog\/clinical-conversations\/wp-json\/wp\/v2\/division?post=17058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}